Poolbeg Pharma upbeat on preliminary influenza drug results

Poolbeg Pharma PLC (OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive after announcing initial data analysis, including a 'clear dose-related response', for its drug, POLB 001, a potential treatment for severe influenza. Skillington says the 'early data readout' indicates that the challenge trial was successful.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.76
+0.00 (0.00%)
AAPL  272.19
+0.00 (0.00%)
AMD  201.06
+0.00 (0.00%)
BAC  54.26
+0.00 (0.00%)
GOOG  303.75
+0.00 (0.00%)
META  664.45
+0.00 (0.00%)
MSFT  483.98
+0.00 (0.00%)
NVDA  174.14
+0.00 (0.00%)
ORCL  180.03
+0.00 (0.00%)
TSLA  483.37
+0.00 (0.00%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.